Biogen Idec Results Mixed

pillsBiogen Idec Inc. (NASDAQ: BIIB) reported fourth-quarter and full-year 2012 results before markets opened this morning. For the quarter, the biotech firm posted adjusted diluted earnings per share (EPS) of $1.40 on revenues of $1.42 billion. In the same period a year ago, the company reported EPS of $1.51 on revenues of $1.33 billion. Fourth-quarter results also compare to the Thomson Reuters consensus estimates for EPS of $1.46 EPS and $1.39 billion in revenues.

For the full year, Biogen Idec posted adjusted EPS of $6.53 on revenues of $5.52 billion, compared with EPS of $5.90 on revenues of $5.05 billion in 2011. The consensus estimate called for EPS of $6.58 on revenues of $5.48 billion.

On a GAAP basis, the company reported fourth-quarter EPS of $1.23 and full-year EPS of $5.76.

The company's CEO said:

We recorded another solid year of revenue growth and profitability, all while advancing our late-stage pipeline and investing in upcoming product launches. We are poised to begin what we expect will be a remarkable period of growth, driven by our promising compounds including TECFIDERA and Peginterferon beta-1a for MS, and both Factor VIII and Factor IX for hemophilia

For 2013, Biogen Idec expects revenues to grow approximately 10% and forecasts adjusted EPS at $7.15 to $7.25, compared with analysts' consensus estimate of $7.27.

Biogen Idec's shares are down about 0.1% in premarket trading, at $146.02 in a 52-week range of $114.53 to $157.18. Thomson Reuters had a consensus analyst price target of around $156.70 before today's report.

Filed under: 24/7 Wall St. Wire, Biotech, Earnings Tagged: BIIB
Read Full Story


NASDAQ 7,234.31 -5.16 -0.07%
S&P 500 2,716.26 -15.96 -0.58%
DJIA 24,964.75 -254.63 -1.01%
NIKKEI 225 21,925.10 -224.11 -1.01%
HANG SENG 30,873.63 -241.80 -0.78%
DAX 12,487.90 102.30 0.83%
USD (per EUR) 1.23 -0.01 -0.50%
USD (per CHF) 0.94 0.01 0.73%
JPY (per USD) 107.28 0.57 0.53%
GBP (per USD) 1.40 0.00 0.01%

Can't get enough business news?

Sign up for Finance Report by AOL and get everything from retailer news to the latest IPOs delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.